Efficacy of Mepolizumab in Patients With Severe Eosinophilic Asthma and Concomitant Severe Chronic Urticaria: An Example of Personalized Medicine?

J Investig Allergol Clin Immunol. 2023 Feb 17;33(1):54-56. doi: 10.18176/jiaci.0770. Epub 2021 Nov 29.

Authors

L Antonicelli¹, C Tontini², M S Garritani¹, M A Piga³, M B Bilò^{1

3}

Affiliations

¹ SOSD Allergologia, Dipartimento di Medicina Interna, Azienda Ospedaliero-Universitaria Ospedali Riuniti, Ancona, Italy.
² Lydia Becker Institute for Immunology and Inflammation, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.
³ Dipartimento di Scienze Cliniche e Molecolari, Universita' Politecnica delle Marche, Ancona, Italy.

PMID: 34842174
DOI: 10.18176/jiaci.0770

No abstract available

Keywords: Efficacy; Mepolizumab; Personalized medicine; Severe eosinophilic asthma; Severe chronic urticaria.

Publication types

Comment

MeSH terms

Anti-Asthmatic Agents* / therapeutic use
Asthma* / complications
Asthma* / drug therapy
Chronic Urticaria*
Humans
Precision Medicine
Pulmonary Eosinophilia* / drug therapy

Substances

mepolizumab
Anti-Asthmatic Agents